M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Abbisko secures CDE Breakthrough Therapy Designation for Irpagratinib in HCC treatment
Shanghai-based oncology biopharma firm Abbisko Therapeutics (HKEX: 02256) announced on Monday that it has received Breakthrough Therapy Designation from China's Center for Drug Evaluation (CDE) for irpagratinib (ABSK011), its highly selective FGFR4 inhibitor, for the treatment of hepatocellular...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search